Adjuvant chemoradiotherapy versus adjuvant chemotherapy for patients with N3 gastric cancer after D2/R0 resection: a retrospective study based on propensity score analyses

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Chang JS, Lim JS, Noh SH, et al. Patterns of regional recurrence after curative D2 resection for stage III (N3) gastric cancer: implications for postoperative radiotherapy. Radiother Oncol. 2012;104(3):367–373. doi:10.1016/j.radonc.2012.08.01722981610
   PubMed Web of Science ®Google Scholar
• Lee J, Lim DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268–273. doi:10.1200/JCO.2011.39.195322184384
   PubMed Web of Science ®Google Scholar
• Kilic L, Ordu C, Ekenel M, et al. Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients? Med Oncol. 2013;30(3):660. doi:10.1007/s12032-013-0660-223877872
   PubMed Web of Science ®Google Scholar
• Fan M, Li G, Shen L, Zhang H, Liang L, Zhang Z. Identification of patients with lymph node metastasis from gastric cancer who may benefit from adjuvant chemoradiotherapy after D2 dissection-do N3 patients benefit from additional radiation? Br J Radiol. 2016;89(1059):20150758. doi:10.1259/bjr.2015075826728420
   PubMed Web of Science ®Google Scholar
• Peng J, Zhou F, Dai J, et al. Benefit from adjuvant chemoradiation to resected stage IIIC gastric cancer patients with D2 lymph node dissection. J Clin Oncol. 2014;32(Suppl):Abstract e15028. doi:10.1200/JCO.2013.54.6911
   Google Scholar
• Nam H, Lim DH, Kim S, et al. A new suggestion for the radiation target volume after a subtotal gastrectomy in patients with stomach cancer. Int J Radiat Oncol Biol Phys. 2008;71(2):448–455. doi:10.1016/j.ijrobp.2007.09.05518234442
   PubMed Web of Science ®Google Scholar
• Lee J, Lim DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial. J Clin Oncol. 2012;30(3):268–273. 22184384
   PubMed Web of Science ®Google Scholar
• Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics. 1998;54(3):948–963. 9750244
   PubMed Web of Science ®Google Scholar
• Chang JS, Kim KH, Yoon HI, et al. Locoregional relapse after gastrectomy with D2 lymphadenectomy for gastric cancer. Br J Surg. 2017;104(7):877–884. doi:10.1002/bjs.1050228245053
   PubMed Web of Science ®Google Scholar
• Dai Q, Jiang L, Lin R, et al. Adjuvant chemoradiotherapy versus chemotherapy for gastric cancer: A meta-analysis of randomized controlled trials. J Surg Oncol. 2015;111(3):277–284. doi:10.1002/jso.2379525273525
   PubMed Web of Science ®Google Scholar
• Huang Y, Yang Q, Zhou S, et al. Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 lymphadenectomy: a meta-analysis. PLoS One. 2013;8(7):e68939. doi:10.1371/journal.pone.006893923874819
   PubMed Web of Science ®Google Scholar
• Zhou ML, Kang M, Li GC, Guo XM, Zhang Z. Postoperative chemoradiotherapy versus chemotherapy for R0 resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysis. World J Surg Oncol. 2016;14(1):209. doi:10.1186/s12957-016-0957-727502921
   PubMedGoogle Scholar
• Park SH, Sohn TS, Lee J, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015;33(28):3130–3136. doi:10.1200/JCO.2014.58.393025559811
   PubMed Web of Science ®Google Scholar
• Chae S, Lee A, Lee JH. The effectiveness of the new (7th) UICC N classification in the prognosis evaluation of gastric cancer patients: a comparative study between the 5th/6th and 7th UICC N classification. Gastric Cancer. 2011;14(2):166–171. doi:10.1007/s10120-011-0024-621360132
   PubMed Web of Science ®Google Scholar
• Chen S, Zhao BW, Li YF, et al. The prognostic value of harvested lymph nodes and the metastatic lymph node ratio for gastric cancer patients: results of a study of 1,101 patients. PLoS One. 2012;7(11):e49424. doi:10.1371/journal.pone.004942423166665
   PubMed Web of Science ®Google Scholar
• Jun KH, Lee JS, Kim JH, Kim JJ, Chin HM, Park SM. The rationality of N3 classification in the 7th edition of the international union against cancer TNM staging system for gastric adenocarcinomas: a case-control study. Int J Surg. 2014;12(9):893–896. doi:10.1016/j.ijsu.2014.06.01425026311
   PubMed Web of Science ®Google Scholar
• Yeh CN, Wang SY, Hsu JT, et al. N3 subclassification incorporated into the final pathologic staging of gastric cancer: a modified system based on current AJCC staging. Medicine (Baltimore). 2015;94(8):e575. doi:10.1097/MD.000000000000087425715257
   PubMed Web of Science ®Google Scholar
• Cheng Y, Huang J, Zhu Z, Xu H. [Rationality of N3 classification and its sub-classification in TNM classification system for advanced gastric cancer]. Zhonghua Wei Chang Wai Ke Za Zhi. 2016;19(7):749–755. 27452751
   PubMedGoogle Scholar
• Li G, Zhang Z, Ma X, Zhu J, Cai G. Postoperative chemoradiotherapy combined with epirubicin-based triplet chemotherapy for locally advanced adenocarcinoma of the stomach or gastroesophageal junction. PLoS One. 2013;8(1):e54233. doi:10.1371/journal.pone.007552523372688
   PubMed Web of Science ®Google Scholar
• Sasako M, Sakuramoto S, Katai H, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–4393. doi:10.1200/JCO.2011.36.590822010012
   PubMed Web of Science ®Google Scholar
• Elimova E, Janjigian YY, Mulcahy M, et al. It is time to stop using epirubicin to treat any patient with gastroesophageal adenocarcinoma. J Clin Oncol. 2017;35(4):475–477. doi:10.1200/JCO.2016.69.727628129519
   PubMed Web of Science ®Google Scholar
• Al-Batran S, Homann N, Schmalenberg H, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. J Clin Oncol. 2017;35(15_suppl):4004.
   Google Scholar
• Al-Batran SE, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 2016;17(12):1697–1708. doi:10.1016/S1470-2045(16)30531-927776843
   PubMed Web of Science ®Google Scholar